"Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial." by Jeff Porter Sharman

Selected Works of John M. Pagel, MD, PhD

Article

Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial.

Journal of Clinical Oncology (2014)

Jeff Porter Sharman, Cancer Institute
Steven E. Coutre, Stanford University
Richard R. Furman, Cornell University
Bruce D. Cheson, Georgetown University
John M. Pagel, Fred Hutchinson Cancer Research Center
Peter Hillmen, St James's University Hospital
Jacqueline Claudia Barrientos, Hofstra University
Andrew David Zelenetz, Memorial Sloan Kettering Cancer Center
Thomas J. Kipps, Ghent University
Ian Flinn, Sarah Cannon Research Institute
Paolo Ghia, Vita-Salute San Raffaele University
Michael J. Hallek, University of Cologne
Bertrand Coiffier, Claude Bernard University Lyon 1
Susan Mary O'Brien, University of Texas MD Anderson Cancer Center
Eugen Tausch, University of Ulm
Karl A Kreuzer, University of Cologne
Wendy Jiang
Thomas Michael Jahn, Children's Hospital Los Angeles
Mirella Lazarov
Stephan Stilgenbauer, University of Ulm

Link

Disciplines

Publication Date

May 20, 2014

Citation Information

Jeff Porter Sharman, Steven E. Coutre, Richard R. Furman, Bruce D. Cheson, et al.. "Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial." Journal of Clinical Oncology Vol. 32 (2014) p. 7011
Available at: http://works.bepress.com/john-pagel/96/